{"id":559689,"date":"2026-06-13T05:00:00","date_gmt":"2026-06-13T03:00:00","guid":{"rendered":"https:\/\/medizinonline.com\/atopic-dermatitis-interesting-news-on-drug-candidates-in-phase-iii\/"},"modified":"2026-06-18T17:18:08","modified_gmt":"2026-06-18T15:18:08","slug":"atopic-dermatitis-interesting-news-on-drug-candidates-in-phase-iii","status":"publish","type":"post","link":"https:\/\/medizinonline.com\/en\/atopic-dermatitis-interesting-news-on-drug-candidates-in-phase-iii\/","title":{"rendered":"Atopic Dermatitis: Interesting News on Drug Candidates in Phase III"},"content":{"rendered":"\n

At the 2026 Annual Meeting of the American Academy of Dermatology<\/em> (AAD), the latest study data on amlitelimab and rademikibart, among other topics, were presented during Late-Breaking Research sessions. The results underscore the therapeutic potential of these drug candidates\u2014key endpoints were met, the safety profile was generally favorable, and, like other monoclonal antibodies, amlitelimab and rademikibart also demonstrate the advantage of convenient long-term use. <\/strong><\/p>\n\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"excerpt":{"rendered":"

At the 2026 Annual Meeting of the American Academy of Dermatology (AAD), the latest study data on amlitelimab and rademikibart, among other topics, were presented during Late-Breaking Research sessions. The……... <\/p>\n

Dieser Inhalt ist nur f\u00fcr Benutzer der Gruppe: Medizinische Fachperson zug\u00e4nglich
Jetzt beitreten<\/a><\/div>
Already a member? Log in here<\/a><\/div><\/div><\/div>","protected":false},"author":7,"featured_media":559690,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"pmpro_default_level":"","cat_1_feature_home_top":false,"cat_2_editor_pick":false,"csco_eyebrow_text":"Highlights from the AAD Annual Meeting","footnotes":""},"category":[11548,11331,11513,11340,11503],"tags":[95002,84914,12624,95124,95126,68865,27671,95127,95125],"powerkit_post_featured":[],"class_list":["post-559689","post","type-post","status-publish","format-standard","has-post-thumbnail","category-rx-en","category-allergology-and-clinical-immunology","category-congress-reports","category-dermatology-and-venereology","category-studies","tag-american-academy-of-dermatology","tag-amlitelimab-en","tag-atopic-dermatitis-en","tag-coast-1","tag-coast-2","tag-drug-candidates","tag-long-term-use","tag-radiant-ad","tag-shore","pmpro-level-required","pmpro-level-1","pmpro-no-access"],"acf":[],"publishpress_future_action":{"enabled":false,"date":"2026-06-26 05:22:03","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"wpml_current_locale":"en_US","wpml_translations":{"fr_FR":{"locale":"fr_FR","id":559692,"slug":"dermatite-atopique-des-nouvelles-interessantes-concernant-les-candidats-medicaments-en-phase-iii","post_title":"Dermatite atopique : des nouvelles int\u00e9ressantes concernant les candidats-m\u00e9dicaments en phase III","href":"https:\/\/medizinonline.com\/fr\/dermatite-atopique-des-nouvelles-interessantes-concernant-les-candidats-medicaments-en-phase-iii\/"},"it_IT":{"locale":"it_IT","id":559695,"slug":"dermatite-atopica-novita-interessanti-sui-principi-attivi-candidati-in-fase-iii","post_title":"Dermatite atopica: novit\u00e0 interessanti sui principi attivi candidati in fase III","href":"https:\/\/medizinonline.com\/it\/dermatite-atopica-novita-interessanti-sui-principi-attivi-candidati-in-fase-iii\/"},"pt_PT":{"locale":"pt_PT","id":559698,"slug":"dermatite-atopica-novidades-interessantes-sobre-candidatos-a-principios-ativos-na-fase-iii","post_title":"Dermatite at\u00f3pica: novidades interessantes sobre candidatos a princ\u00edpios ativos na Fase III","href":"https:\/\/medizinonline.com\/pt-pt\/dermatite-atopica-novidades-interessantes-sobre-candidatos-a-principios-ativos-na-fase-iii\/"},"es_ES":{"locale":"es_ES","id":559684,"slug":"dermatitis-atopica-novedades-interesantes-sobre-los-candidatos-a-farmacos-en-fase-iii","post_title":"Dermatitis at\u00f3pica: novedades interesantes sobre los candidatos a f\u00e1rmacos en fase III","href":"https:\/\/medizinonline.com\/es\/dermatitis-atopica-novedades-interesantes-sobre-los-candidatos-a-farmacos-en-fase-iii\/"}},"_links":{"self":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/559689","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/users\/7"}],"replies":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/comments?post=559689"}],"version-history":[{"count":1,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/559689\/revisions"}],"predecessor-version":[{"id":559691,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/posts\/559689\/revisions\/559691"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media\/559690"}],"wp:attachment":[{"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/media?parent=559689"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/category?post=559689"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/tags?post=559689"},{"taxonomy":"powerkit_post_featured","embeddable":true,"href":"https:\/\/medizinonline.com\/en\/wp-json\/wp\/v2\/powerkit_post_featured?post=559689"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}